Items

• 2023-07-21

  A Year of Betrayal

  This doesn't need to be long I am just glad to have a way to express how incredibly disappointed I have been throughout the course of this pandemic. In the first few months after the outbreak, most of us relied heavily on the public governmental briefings by Dr Fauci and others, and we eagerly awaited the development of tests and vaccines by the pharmaceutical industry. We trusted that our government and our doctors were working earnestly to provide good solutions to a terrible problem, quickly. But if we fast forward a few years, what a horrible change has transpired! Pretty much everyone who we trusted at the beginning of the pandemic has been proven either a downright liar or to have been working for their own private interests all along. Dr Fauci couldn't get his story straight - repeatedly - over simple matters, and lied again and again about the connection between the virus, the government, and the Wuhan virology lab. Though various remedies (like ivermectin) were decried as malicious and dangerous, we now know that the pharmaceutical companies we were busy trusting were pushing to consider the use of ivermectin medical malpractice, because they wanted an emergency use authorization for their insufficiently tested and experimental vaccines. Some of us already knew we couldn't trust our government, but most of us hoped that we could at least trust our doctors. What a disappointment.
• 
  2022-04-19

  GB Oral History, 2022/04/19

  The interviewee discusses vaccine hesitancy and life during the pandemic without having received the vaccine.
• 
  2021-04-06

  News Article: Pfizer Injects AI Into Vaccine Trials

  This sub-article was the lead item in this week's Wall Street Journal PRO "Artificial Intelligence Weekly" email blast: "By Angus Loten Welcome back. Artificial intelligence is set to take a decisive role in shaping the post-pandemic economy, from helping employers reopen workplaces to getting supply chains back on track. Corporate technology leaders and industry analysts offered these and other insights at last week’s virtual edition of the WSJ Pro AI Executive Forum. Some of their views are outlined in the sections below. One broad takeaway: Though still in its infancy, AI is already having a profound impact on our daily lives. Pfizer’s Speedy Vaccine Rollout Pfizer Inc. last year developed AI-powered dashboards designed to monitor the effect of Covid-19 on clinical trials in real time, ultimately helping the pharmaceutical giant roll out its coronavirus vaccination in less than a year, The Wall Street Journal’s Sara Castellanos reports. A shot in the arm. Pfizer fed large amounts of case-rate data into AI-enabled predictive models to quickly generate site selection for clinical trials, said Lidia Fonseca, the company’s chief digital and technology officer. A smart move. Pfizer two years ago began experimenting with the emerging technologies, focusing on digital tools that promised to offer better outcomes for patients, doctors and employees, with results it was able to draw on during the pandemic, Ms. Fonseca said."
• 
  2020-11-25

  コロナワクチン市場供給へ　中国で初めて申請(2020年11月25日) - First application in China to supply the corona vaccine market (November 25, 2020)コロナワクチン市場供給へ　中国で初めて申請(2020年11月25日) - First application in China to supply the corona vaccine market (November 25, 2020)

  中国で初めてワクチンの市場への供給許可が申請されました。 　中国メディアによりますと、国有の製薬大手「シノファーム」は7月からすでに緊急的な投与を開始している開発中の新型コロナウイルスのワクチンについて、市場への供給許可を当局に申請しました。シノファームは現在、南米のペルーなどで最終となる第3段階の臨床試験をしていて、当局はこの結果を踏まえて許可を出すとしています。シノファームは「100万人近くにワクチンを緊急投与したが、深刻な副作用の報告は1件もなく、ほんの少数に軽度の症状がみられた」と説明しています。 For the first time in China, an application of license to supply vaccines to the market has been put in. According to the Chinese media, the state-owned pharmaceutical giant "Sinofarm" has applied to the authorities for permission to supply the new coronavirus vaccine under development, which has already started emergency administration since July. Shinofarm is currently conducting the final third-stage clinical trials in Peru and other parts of South America, and the authorities will issue a permit based on this result. "We urgently administered the vaccine to nearly one million people, but there were no reports of serious side effects, and only a few had mild symptoms," explains Shinofarm. Video translated by Youngbin Noh
• 
  2020-04-30

  The Essential People Project: Cedric Masengere

  As part of Everyday Boston's Essential People Project, Kamal Oliver interviews Cedric Masengere. Cedric is a manufacturing associate at Moderna, and the interview explores his journey from an 8-year-old playing with chemicals in his bedroom to the floor of the pharmaceutical company working to produce a vaccine during the pandemic.